Neoantigens expressed in ovarian cancer and their uses
US11945881B2 · kind B2 · utility
0Cited by
80References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2021 |
| Grant date | Apr 2, 2024 |
| Priority date | — |
| Expiry date | Sep 27, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24041
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to ovarian cancer neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the ovarian cancer neoantigens, and methods of making and using them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.